Pharma, Medical & Biotech

M&A ToolkitPharma, Medical & BiotechPodcast

Dealcast: Allergan reaction

The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.

Elisa Basili Elisa Basili Speakers, Acuris
Anya Cummins on the challenges and opportunities facing Irish M&A
IrelandAcquisition FinanceMacro ViewsPrivate EquityPublic M&APharma, Medical & BiotechTechnology

Anya Cummins on the challenges and opportunities facing Irish M&A

A year on from the last time we sat down with Anya Cummins, Partner and Head of M&A at Deloitte we wanted to see if there is any more certainty around Brexit since Article 50 was triggered. We were also keen to find out what the deal drivers are for Irish M&A and PE investments in the next 12 months. 

Load more